Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina

J Ocul Pharmacol Ther. 2007 Aug;23(4):321-34. doi: 10.1089/jop.2006.0150.

Abstract

Purpose: The overall aim of this research work was to evaluate a series of dipeptide monoester prodrugs of an antiviral agent, ganciclovir (GCV), for oligopeptide transporter-targeted transscleral drug delivery to rabbit retina.

Methods: The permeability and enzymatic hydrolysis of dipeptide monoester GCV prodrugs were evaluated using freshly excized rabbit retinal pigment epithelium (RPE)-choroidsclera (RCS) and sclera tissue preparations. Affinity and transport mechanism of these prodrugs and their translocation across RCS were investigated through competitive inhibition studies of [(3)H]glycylsarcosine with the prodrugs.

Results: The transport of glycylsarcosine was found to be saturable (K(m) = 1.21 +/- 0.41 mM, V(max) = 15.89 +/- 1.54 pmoles/min/cm(2)), pH, temperature, and energy dependant. Dipeptides, angiotensin converting enzyme inhibitors, and a beta-lactum antibiotic strongly inhibited the transport of glycylsarcosine indicating the functional presence of oligopeptide transport (OPT) system on the RPE. Dipeptide prodrugs (valine-valine-GCV, glycine-valine-GCV, and tyrosine-valine-GCV), and valine-GCV demonstrate a high enzymatic stability and affinity toward the retinal OPT system. The transport of the prodrugs was significantly inhibited ( approximately 50%) in the presence of glycylsarcosine. The rank order of scleral permeability was Gly-Val-GCV approximately GCV>Val-GCV>Tyr-Val-GCV approximately Val-Val-GCV. The RCS permeability values of Val-GCV (3.29 +/- 0.09 x 10(6)cm/s), Val-Val-GCV (4.14 +/- 0.33 x 10(6)cm/s), Gly-Val-GCV (3.40 +/- 0.47 x 10(6)cm/s) and Tyr-Val-GCV (3.08 +/- 0.29 x 10(6)cm/s) were two-fold higher than that of GCV (1.61 +/- 0.06 x 10(6)cm/s).

Conclusions: The dipeptide monoester GCV prodrugs, owning to higher lipophilicity and OPT-mediated translocation across RPE, appear to be promising candidates in the treatment of ocular cytomegalovirus infections following an episcleral administration.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacokinetics*
  • Biological Transport
  • Carrier Proteins / metabolism
  • Choroid / metabolism
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacokinetics
  • Drug Delivery Systems*
  • Ganciclovir / administration & dosage
  • Ganciclovir / analogs & derivatives
  • Ganciclovir / pharmacokinetics*
  • In Vitro Techniques
  • Male
  • Oligopeptides / metabolism
  • Pigment Epithelium of Eye / metabolism
  • Prodrugs / administration & dosage
  • Prodrugs / pharmacokinetics
  • Rabbits
  • Retina / metabolism*
  • Sclera / metabolism
  • Structure-Activity Relationship

Substances

  • Antiviral Agents
  • Carrier Proteins
  • Dipeptides
  • Oligopeptides
  • Prodrugs
  • glycylsarcosine
  • Ganciclovir